The Canadian Immunization Monitoring Program, ACTive (IMPACT): Active surveillance for vaccine adverse events and vaccine-preventable diseases

Bettinger, Julie A.; Halperin, SA; Vaudry, Wendy; Law, Barbara; Scheifele, David W.

doi:10.14745/ccdr.v40is3a06

Cited by 17 publications

(17 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This proportion is slightly higher than that reported in the United States for the same time period (5%) and compared to previous years in Canada, but lower than that reported in Australia in 2015 (15%) (17,28,33). The majority of SAEs occurred in children and adolescents, which may in part be due to IMPACT, which contributes over half of all serious AEFI reports for those under the age of 18 years and looks for specific surveillance targets in children (20,34). At the time of reporting, the majority of the SAEs had fully recovered.…”

Section: Discussionmentioning

confidence: 99%

Vaccine safety surveillance in Canada: Reports to CAEFISS, 2013–2016

Ahmadipour

Watkins

Fréchette

et al. 2018

CCDR

View full text Add to dashboard Cite

Background: Canada has one of the strongest vaccine safety surveillance systems in the world. This system includes both passive surveillance of all vaccines administered and active surveillance of all childhood vaccines. Objectives: To provide 1) a descriptive analysis of the adverse events following immunization (AEFI) reports for vaccines administered in Canada, 2) an analysis of serious adverse events (SAEs) and 3) a list of the top ten groups of vaccines with the highest reporting rates. Methods: Descriptive analyses were conducted of AEFI reports received by the Public Health Agency of Canada (PHAC) by August 14, 2017, for vaccines marketed in Canada and administered from January 1, 2013 to December 31, 2016. Data elements in this analysis include: type of surveillance program, AEFIs, demographics, health care utilization, outcome, seriousness of adverse events and type of vaccine. Results: Over the four year period, 11,079 AEFI reports were received from across Canada. The average annual AEFI reporting rate was 13.4/100,000 doses distributed in Canada for vaccines administered during 2013-2016 and was found to be inversely proportional to age. The majority of reports (92%) were non-serious events, involving vaccination site reactions rash, and allergic events. Overall, there were 892 SAE reports, for a reporting rate of 1.1/100,000 doses distributed during 2013-2016. Of the SAE reports, the most common primary AEFIs were anaphylaxis followed by seizure. Meningococcal serogroup C conjugate vaccines (given concomitantly) were responsible for the highest rates of AEFIs, at 91.6 per 100,000 doses distributed. There were no unexpected vaccine safety issues identified or increases in frequency or severity of expected adverse events. Conclusion: Canada's continuous monitoring of the safety of marketed vaccines during 2013-2016 did not identify any increase in the frequency or severity of AEFIs, previously unknown AEFIs, or areas that required further investigation or research. Vaccines marketed in Canada continue to have an excellent safety profile.

show abstract

Section: Discussionmentioning

confidence: 99%

Vaccine safety surveillance in Canada: Reports to CAEFISS, 2013–2016

Ahmadipour

Watkins

Fréchette

et al. 2018

CCDR

View full text Add to dashboard Cite

show abstract

“…IMPACT hospitals account for over 90% of tertiary care pediatric beds in Canada (10,11). Invasive H. influenzae disease (all serotypes) has been monitored since 2007.…”

Section: Dr David Scheifelementioning

confidence: 99%

Developing a vaccine for Haemophilus influenzae serotype a: Proceedings of a workshop

Cox¹,

Barreto²,

Ulanova³

et al. 2017

Canada Communicable Disease Report

View full text Add to dashboard Cite

show abstract

“…Furthermore, despite the regular release of quarterly public safety postings, the timeliness of the data exchange flow could be improved (6,15). Over the next three years, the plan for IMPACT to transition to electronic reporting will enable faster transmission and follow-up of information (5). While IMPACT captures approximately 90% of paediatric tertiary care beds in Canada, it would be useful to improve the representation in Ontario and, ideally, capture all paediatric admissions in the country (5).…”

Section: Optimizationmentioning

confidence: 99%

“…Over the next three years, the plan for IMPACT to transition to electronic reporting will enable faster transmission and follow-up of information (5). While IMPACT captures approximately 90% of paediatric tertiary care beds in Canada, it would be useful to improve the representation in Ontario and, ideally, capture all paediatric admissions in the country (5). Finally, the work of the Vaccine Vigilance Working Group to create an AEFI Signal Response Protocol that will describe the critical processes and required actions for timely management of any newly detected or emerging vaccine safety signals is still ongoing, long after the establishment of the Working Group itself (3).…”

Section: Optimizationmentioning

confidence: 99%

“…The six papers presented in this supplement on vaccine safety (3,4,5,6,7,8) have been specially selected to collectively represent a series of complementary aspects of what goes into vaccine vigilance: monitoring, signal generation, investigation and response, together with the role of research networks that allow for quick implementation of vaccine research and clinical trials. They highlight the best assets of Canadian vaccine vigilance and provide examples of provincial/territorial resources, activities and capacity.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Vaccine vigilance in Canada: Is it as robust as it could be?

Duclos

2014

CCDR

View full text Add to dashboard Cite

Canada has been known to have one of the better vaccine safety surveillance capacities in the world, but in the early 2000s, it was noted there was still room for improvement. How has Canada done over the last decade and is there more to be done? Canada has done well. First, there has been significant progress made by the Vaccine Vigilance Working Group to enhance the passive vaccine safety monitoring system and address potential issues arising from the review of surveillance data and cases or clusters of concern. Second, there has been an increased investigative capacity for clusters of adverse events and other vaccine safety issues, including an assessment and referral system for individuals with adverse events following immunizations (AEFIs). Third, the use of the Brighton Collaboration definitions and other international standards has facilitated international collaboration and represents the best standard of practice. Despite all these improvements, however, there is more that could be done. The sensitivity of Canada's passive surveillance system still varies from one province and territory to another. The timeliness of the data exchange flow could improve. The AEFI Signal Response Protocol, which identifies the processes and required actions for timely management of any newly detected or emerging vaccine safety signals, is a critical piece of a robust vaccine safety system but it is still in the making. It is commendable that Canada has decided to expand its focus on evaluation research from influenza vaccines to vaccine-preventable diseases more broadly, with the establishment of the Canadian Immunization Research Network (CIRN). CIRN's newly developed Provincial Collaborative Network and the move toward record linkages is excellent. These new investments are welcome in light of the rich vaccine development pipeline, the increased pool of available vaccines, and the growing set of technologies for vaccines production, delivery, and safety monitoring. What would round this all out would be a stronger capacity to monitor the implementation of vaccination programs and vaccine coverage, and better documentation of the reduction of the disease burden attributable to vaccination programs. Canada's investment in vaccines for the health of all deserves no less.

show abstract

The Canadian Immunization Monitoring Program, ACTive (IMPACT): Active surveillance for vaccine adverse events and vaccine-preventable diseases

Cited by 17 publications

References 8 publications

Vaccine safety surveillance in Canada: Reports to CAEFISS, 2013–2016

Vaccine safety surveillance in Canada: Reports to CAEFISS, 2013–2016

Developing a vaccine for Haemophilus influenzae serotype a: Proceedings of a workshop

Vaccine vigilance in Canada: Is it as robust as it could be?

Contact Info

Product

Resources

About